UK markets open in 5 hours 23 minutes
  • NIKKEI 225

    28,241.53
    +314.16 (+1.12%)
     
  • HANG SENG

    23,565.98
    +216.60 (+0.93%)
     
  • CRUDE OIL

    70.10
    +0.61 (+0.88%)
     
  • GOLD FUTURES

    1,780.80
    +1.30 (+0.07%)
     
  • DOW

    35,227.03
    +646.95 (+1.87%)
     
  • BTC-GBP

    38,314.02
    +1,363.62 (+3.69%)
     
  • CMC Crypto 200

    1,312.18
    +52.02 (+4.13%)
     
  • ^IXIC

    15,225.15
    +139.68 (+0.93%)
     
  • ^FTAS

    4,117.60
    +58.28 (+1.44%)
     

Genenta Announces Filing of Registration Statement for Proposed Initial Public Offering

·3-min read

MILAN, Italy and NEW YORK, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Genenta Science, a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for cancer (Temferon™), announced today that it has filed a registration statement on Form F-1 (the “Registration Statement”) with the U.S. Securities and Exchange Commission (“SEC”) relating to a proposed initial public offering of the Company’s ordinary shares, to be delivered in the form of American Depositary Shares (“ADSs”). The number and price of the securities to be sold in the offering has not yet been determined.

The Company has applied to list the ADSs on the Nasdaq Capital Market in the United States under the symbol "GNTA" (file number 333-260923). ADSs are U.S. dollar-denominated negotiable instruments issued by a depositary bank that facilitate U.S. trading and investment in shares of non-U.S. companies. Each ADS represents the right to receive one ordinary share.

Roth Capital Partners is acting as sole book-running manager of the offering. Maxim Group LLC is acting as lead manager of the offering.

The Registration Statement on Form F-1 relating to the proposed sale of these securities has been filed with the SEC but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the Registration Statement becomes effective.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of any securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Any potential offering is subject to market and other conditions.

The proposed offering of ADSs will only be made by means of a prospectus. When a copy of the preliminary prospectus relating to the offering is available, copies may be obtained from Roth Capital Partners, 888 San Clemente Drive, Newport Beach, CA 92660, Attention: Equity Capital Markets at (800) 678-9147 or by email at rothecm@roth.com; or from Maxim Group LLC at 300 Park Avenue, 16th Floor, New York, NY 10022, Attention: Syndicate Department, or by telephone at (212) 895-3745 or by email at syndicate@maximgrp.com.

About Genenta Science
Genenta (www.genenta.com) is a clinical-stage biotechnology company pioneering the development of a proprietary hematopoietic stem cell gene therapy for the treatment of a variety of cancers. Temferon™ is based on ex-vivo gene transfer into autologous hematopoietic stem/progenitor cells (HSPCs) to deliver immunomodulatory molecules directly via tumor-infiltrating monocytes/macrophages (Tie2 Expressing Monocytes - TEMs). Temferon™, which is under investigation in a Phase I/IIa clinical trial in newly diagnosed Glioblastoma Multiforme patients, is not restricted to pre-selected tumor antigens nor type and may reach solid tumors, one of the main unresolved challenges in immuno-oncology. Based in Milan, Italy, and New York, USA.

Investor Relations - LifeSci Advisors:

Genenta Media/Investor Contact

Mary-Ann Chang, CFA

Stefania Mazzoleni, PhD

+44 7483 28 48 53

+39 339 709 59 31

mchang@lifesciadvisors.com

stefania.mazzoleni@genenta.com


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting